Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water.

Abstract: Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time.

Abstract: Provided are novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof, in the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is —C(?O)—NH—, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.

Abstract: A novel means for improving sleep quality etc. is provided. Provided is a composition for sleep quality improvement that contains kaempferol and/or a glycoside thereof.

Abstract: A combination of antitumor agents significantly shrinks tumors by synergistic antitumor action without increasing side effects to the extent possible. The antitumor composition contains compound (B) or a salt thereof for use in combination with antitumor agent (A), where (A) is at least one antitumor agent selected from alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors; and (B) is a compound or a salt thereof represented by formula (1): where R1 is halogen, aryl, aryloxy, or lower alkyl optionally substituted with one or more halogen atoms; R2 is hydrogen, halogen, lower alkyl, or lower alkoxy; and m=1 to 3, provided that when m is 2 or 3, each R1 is the same or different.

Abstract: The present application provides a phytin with improved solubility in water, wherein the phytin comprises calcium and/or magnesium with specific of molar ratios to phytic acid.

Abstract: The disclosure provides a frozen dessert composition including (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition. The disclosure also provides a method of manufacturing a frozen dessert composition including mixing the following components with water; (A) about 6 to 15% by weight of palatinose based on the total weight of the composition, and (B) about 10 to 30% by weight of a dextrin or a combination of a dextrin and a soluble dietary fiber based on the total weight of the composition.

Abstract: The present invention relates to providing a detection device that uses surface plasmon resonance to detect the presence or the amount of a substance to be detected, in which a detection unit can accurately detect scattered light without detecting stray light, and can accurately determine an irradiation angle of excitation light. This detection method uses the detection device that uses surface plasmon resonance to detect the presence or the amount of a substance to be detected. A detection range control unit controls a detection range of a detection unit so that a detection range utilized when the detection unit detects scattered light emitted from a metallic film and front a region on the metallic film differs from a detection range utilized when the detection unit detects fluorescence emitted front a fluorescent substance labeling the substance to be detected winch has been captured by a capturing body.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: Provided is a heat shock protein expression-inducing agent, more specifically, a heat shock protein expression-inducing agent comprising a compound represented by formula (I): wherein R is a lower alkyl, phenyl, or hydroxyphenyl, or a salt thereof.

Abstract: The invention relates to methods of synthesizing 2?-deoxy-2?,2?-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.

Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4 -yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.

Abstract: Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.

Abstract: The present invention provides a novel compound having an excellent antitumor effect, stability and metabolic stability. The compound of the present invention is represented by the following general formula (1) wherein R1 represents a halogen atom, an aryl group, an aryloxy group or a lower alkyl group optionally substituted with one or more halogen atoms; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; and; m represents an integer of 1 to 3; provided that when m represents 2 or 3, R1s are the same or different.

Abstract: Provided is a therapeutic agent for ADHD having an efficacy comparable to that of central nervous system stimulants and the same low risk of drug dependence and abuse as existing non-central nervous system stimulants, more particularly a compound represented by formula [I]: wherein each symbol is as defined in the description, or a salt thereof.

Abstract: The present invention provides an agent for treating malignant tumor, comprising a compound of formula (1): wherein R1 to R4 are hydrogen atom, halogen, or etc., Y is optionally-substituted alkylene group or etc.

Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

Abstract: The present disclosure relates to a Lactobacillus paracasei strain having polyamine production promoting activity in an organism, as well as its application and relevant technologies. The present disclosure also relates to the use of the Lactobacillus paracasei strain to promote polyamine production in humans and animals, which may be used, for instance, to reduce hepatic neutral fat. The present disclosure also relates to the use of the Lactobacillus paracasei strain as an agent to prevent or treat a disease, including fatty liver, non-alcoholic steatohepatitis, and liver cirrhosis.

Abstract: Systems and methods for monitoring a receiver assembly configured to detect an ingestible event marker signal, the receiver including a disposable component and a reusable component. The methods can include monitoring the skin impedance experienced by the electrodes of the receiver assembly to determine whether the receiver assembly has poor contact quality or is off-body to notify the user accordingly. The methods can also include monitoring a power source level of the receiver assembly, which can be normalized according to the temperature of the receiver assembly, to determine when the power source is at a critical level to notify the user accordingly.

Abstract: Provided is a pyrazolo[1,5-a]pyrimidine compound represented by the general formula [I]: wherein each symbol is as defined in the description, or a salt thereof, having PAR2 inhibitory activity, and a pharmaceutical composition comprising the same.